Video

Certara’s Phoenix Platform – The world’s most trusted platform for PK/PD analysis and modeling

Today’s drug candidates are more complex than ever. But with development decisions on the line,…

CertaraFebruary 12, 2025

Publication

Population pharmacokinetics of levetiracetam in Chinese adult epilepsy patients with varying renal function

Learn how creatinine clearance drives levetiracetam clearance; PopPK modelling supports renal‑adjusted dosing using Phoenix NLME.

CertaraFebruary 10, 2025

Poster

Simulations to Inform Dose Selection for a Phase 2b Trial Investigating TOUR006, a Fully Human Anti-IL6 Antibody, for Treatment of Thyroid Eye Disease

CertaraFebruary 7, 2025

On-Demand Webinar

Machine Learning for Population PK Model Selection: Theory and Practice

Three of Certara's expert modelers provide a gentle introduction to machine learning in our field.…

CertaraFebruary 7, 2025

On-Demand Webinar

Simcyp Version 24: Advancing PBPK capabilities and translating new science and technology into regulatory-accepted predictive modeling

With the release of Version 24, the Simcyp Simulator introduces cutting-edge enhancements that further elevate…

CertaraFebruary 7, 2025

Publication

Population Pharmacokinetic and Pharmacodynamic Analysis of Navtemadlin in Patients with Relapsed and Refractory (R/R) Myelofibrosis (MF) and Other Myeloid or Solid Tumor Malignancies

This study conducted a population pharmacokinetic (PK) and pharmacodynamic (PD) analysis of navtemadlin, an MDM2…

CertaraFebruary 6, 2025

Publication

Bioequivalence of Water-Soluble Progesterone Injection (GenSci070) in Healthy Chinese Postmenopausal Women Volunteers

Find out how GenSci070 shows bioequivalence and comparable safety to reference progesterone injection in a…

CertaraJanuary 30, 2025

Publication

Understanding Variability in CAR-T Cell Therapy Kinetics

Axicabtagene ciloleucel (axi-cel), a CAR-T cell therapy for relapsed and refractory non-Hodgkin’s lymphoma (NHL), demonstrates…

CertaraJanuary 23, 2025

Publication

Comparison of RT-qPCR With Branched DNA to Quantify a Lipid Nanoparticle-Encapsulated mRNA Therapeutic in Serum and Liver Tissue Samples From Nonclinical PK Studies

Explore how RT‑qPCR provides a viable alternative to bDNA for mRNA‑LNP PK analysis, with comparable…

CertaraJanuary 16, 2025

On-Demand Webinar

Solving Drug Development Challenges with Model-Based Meta-Analysis (MBMA)

In this on-demand webinar, "MBMA: Optimizing Drug Development with Aggregate Clinical Trial Data and Predictive…

CertaraJanuary 9, 2025

Modeling and Simulation

Certara’s Phoenix Platform – The world’s most trusted platform for PK/PD analysis and modeling

Population pharmacokinetics of levetiracetam in Chinese adult epilepsy patients with varying renal function

Simulations to Inform Dose Selection for a Phase 2b Trial Investigating TOUR006, a Fully Human Anti-IL6 Antibody, for Treatment of Thyroid Eye Disease

Machine Learning for Population PK Model Selection: Theory and Practice

Simcyp Version 24: Advancing PBPK capabilities and translating new science and technology into regulatory-accepted predictive modeling

Population Pharmacokinetic and Pharmacodynamic Analysis of Navtemadlin in Patients with Relapsed and Refractory (R/R) Myelofibrosis (MF) and Other Myeloid or Solid Tumor Malignancies

Bioequivalence of Water-Soluble Progesterone Injection (GenSci070) in Healthy Chinese Postmenopausal Women Volunteers

Understanding Variability in CAR-T Cell Therapy Kinetics

Comparison of RT-qPCR With Branched DNA to Quantify a Lipid Nanoparticle-Encapsulated mRNA Therapeutic in Serum and Liver Tissue Samples From Nonclinical PK Studies

Solving Drug Development Challenges with Model-Based Meta-Analysis (MBMA)

Newsletter sign up

Quick links

Solutions

Contact